Antisense modulation of MHC class II transactivator expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of MHC class II transactivator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MHC class II transactivator. Methods of using these compounds for modulation of MHC class II transactivator expression and for treatment of diseases associated with expression of MHC class II transactivator are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding MHC class II transactivator, wherein said compound specifically hybridizes with said nucleic acid molecule encoding MHC class II transactivator and inhibits the expression of MHC class II transactivator.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding MHC class II transactivator.
Dependencies are inferred from the claim text.